Special Issue on paediatric oncology

Prof Tezer Kutluk - Hacettepe University Faculty of Medicine & Cancer Institute, Sıhhiye-Ankara, Turkey
Special Issue on paediatric oncology ( Prof Tezer Kutluk - Hacettepe University Faculty of Medicine & Cancer Institute, Sıhhiye-Ankara, Turkey )
28 Feb 2024

Global trends and inequalities in breast cancer survival and care

Prof Claudia Allemani, Dr Ophira Ginsburg, Prof Vesna Zadnik
Global trends and inequalities in breast cancer survival and care ( Prof Claudia Allemani, Dr Ophira Ginsburg, Prof Vesna Zadnik )
22 Feb 2024

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024

Global Coalition for Radiotherapy - How to integrate radiotherapy in cancer control plans

Prof Richard Sullivan, Dr Lisa Stevens and Prof Pat Price
Global Coalition for Radiotherapy - How to integrate radiotherapy in cancer control plans ( Prof Richard Sullivan, Dr Lisa Stevens and Prof Pat Price )
12 Feb 2024

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )
9 Feb 2024

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )
8 Feb 2024

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA
Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea  Apolo - National Cancer Institute, Bethesda, USA )
5 Feb 2024

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura
ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )
31 Jan 2024

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
31 Jan 2024

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA
Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )
30 Jan 2024

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France
What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )
25 Jan 2024

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )
25 Jan 2024